Olexandra Roman

Olexandra Roman

Auto-generated profile, based on publicly available information

Olexandra Roman

Danylo Halytsky Lviv National Medical University

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2016 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
DHDmytro Havrylyuk
Dmytro Havrylyuk
OROlexandra Roman
Olexandra Roman
Roman LesykRoman Lesyk
Roman Lesyk

31 October 2025 in ScienceRise: Pharmaceutical Science
Verified
Journal Article
Open access
PDF file
DMDmytro Mural
Dmytro Mural
Dmytro KhylyukDmytro Khylyuk
Dmytro Khylyuk
ALAndrii Lozynskyi
Andrii Lozynskyi
VGVictoriya A. Georgiyants
Victoriya A. Georgiyants
OROlexandra Roman
Olexandra Roman
Roman LesykRoman Lesyk
Roman Lesyk
Infectious diseases and cancer remain leading global health challenges, with rising resistance to existing antibiotics and limited selectivity of many cytotoxic agents. Heterocyclic scaffolds, particularly thiazolidinones, offer a promising platform for the development of novel antimicrobial and anticancer compounds. The aim of the study. To evaluate the antimicrobial and cytotoxic properties of thiazolidinone-based compounds against a panel of pathogenic microorganisms and human cancer cell lines, and to identify the most promising derivatives with favorable safety, pharmacokinetic, and mechanistic profiles through molecular docking and dynamics studies. Materials and methods. A library of 5-enamine(hydrazine)-4-thiazolidinone derivatives was screened for antimicrobial activity against Gram-positive and Gram-negative bacteria and Candida albicans, and for cytotoxic activity against six human cancer cell lines. Minimum inhibitory concentrations (MIC) were determined, and IC₅₀ values were measured for selected compounds. Pharmacokinetic properties, including gastrointestinal absorption and lipophilicity, were assessed in silico. To investigate potential mechanisms of antibacterial action, molecular docking was performed against MurB (UDP-N-acetylenolpyruvylglucosamine reductase) and DNA gyrase subunit B (ATPase domain), followed by molecular dynamics (MD) simulations to evaluate the stability of the most promising complexes. Results. Thirty-two compounds exhibited antimicrobial activity (MIC ≤ 200 µM), and ten (6, 7, 10, 12, 13, 16, 19, 21, 22, and 29) were identified as the most active. Compound 29, an isatin–oxadiazole hybrid, demonstrated potent activity against Enterococcus faecalis and vancomycin-resistant E. faecium (MIC = 3.13 µM), outperforming vancomycin. Compound 21 was highly active against Staphylococcus epidermidis (MIC = 1.56 µM), while compound 6 showed efficacy against methicillin-susceptible and -resistant S. aureus (MIC = 6.25 µM). Moderate antifungal activity was observed for compound 27 (MIC = 100 µM), whereas Gram-negative bacteria were largely resistant. Cytotoxicity screening revealed selective anticancer activity of compounds 12 and 27, with high therapeutic indices against CCRF-CEM cells and minimal effects on normal fibroblasts. Compound 2 exhibited strong cytotoxicity (IC₅₀ = 1.1 µM), while compound 29 combined non-cytotoxicity with favorable pharmacokinetic characteristics. Molecular docking supported MurB as the primary antibacterial target, with the most active compounds (21 and 29) showing the most favorable binding energies. Compound 29 also exhibited strong affinity for GyrB, indicating a potential dual-target mechanism. Molecular dynamics confirmed that MurB–compound 29 complexes were particularly stable, correlating well with experimental antibacterial activity. Conclusions. Thiazolidinone-based hybrids demonstrated promising antimicrobial and anticancer properties. Compound 29 emerged as a particularly attractive dual-purpose candidate due to its potent activity, safety profile, favorable pharmacokinetics, and validated interaction with essential bacterial enzymes. Together, biological and computational results support the potential of thiazolidinone scaffolds as a basis for the development of selective or multitarget therapeutic agents

30 August 2025 in ScienceRise: Pharmaceutical Science
Verified
Journal Article
Open access
PDF file
Maryna StasevychMaryna Stasevych
Maryna Stasevych
MHMykhailo Hoidyk
Mykhailo Hoidyk
OROlexandra Roman
Olexandra Roman
RKRoksolana Konechna
Roksolana Konechna
AKAndriy Karkhut
Andriy Karkhut
Roman LesykRoman Lesyk
Roman Lesyk
Epilepsy affects approximately 50 million people globally, with one-third of patients remaining resistant to available therapies, emphasizing the need for new and safer anticonvulsants. Although fragment-based and in silico approaches are effective for drug discovery, a unified structural analysis of antiepileptic APIs on the Ukrainian market remains unexplored. The aim of the study. To analyze 16 antiepileptic APIs registered in Ukraine using fragment-based methods to identify shared pharmacophoric features, structural similarities, and correlations between structural fragments and ADME properties (including drug-likeness patterns for structure-property insights) as a basis for rational anticonvulsant design. Materials and methods. Data were collected from the State Register of Medicinal Products of Ukraine and Compendium (June 2025) using ATC code N03A. Literature review used PubMed, PubChem, DrugBank, Scopus, Elicit, and ResearchRabbit. Structural analysis was performed using Python libraries. Results. The study classified 16 active pharmaceutical ingredients (APIs) into structural clusters (e.g., barbiturates, dibenzazepines, amino acid derivatives) based on Tanimoto similarity coefficients and ECFP4 molecular fingerprints. Commonly identified fragments included carbonyl, amino, amide, carboxyl groups, and aromatic rings. ADME profiling revealed consistent relationships between structural features and physicochemical properties: high lipophilicity in benzodiazepines and good absorption characteristics in gabapentinoids. This analysis was performed to identify structure-dependent ADME patterns, providing a basis for fragment-based design of novel anticonvulsants. Conclusions. Despite chemical diversity, the analyzed APIs exhibit shared spatial pharmacophore arrangements with recurring groups supporting activity at NaV, CaV, GABA-A, SV2A, and GABA-T. ADME profiling and structure–property correlations provide a basis for pharmacophore fragment modelling and CNS-oriented fragment-library design to enable rational discovery. Future design should leverage the identified pharmacophoric fragments to build multitarget molecules within a CNS ADME window